Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM and Lee WS
------>authors3_c=None
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=2
------>paper_class2=1
------>vol=66
------>confirm_bywho=chlin
------>insert_bywho=chlin
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=271
------>medlineContent=
------>unit=E0200
------>insert_date=20030430
------>iam=5
------>update_date=
------>author=???
------>change_event=4
------>ISSN=None
------>authors_c=None
------>score=500
------>journal_name=Biochem. Pharmacol.
------>paper_name=YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway
------>confirm_date=20050401
------>tch_id=085007
------>pmid=12826268
------>page1=263
------>fullAbstract=This study was designed to investigate the effect of YC-1, 3-(5~-hydroxymethyl-2~-furyl)-1-benzylindazole, in human umbilical vein endothelial cells (HUVECs) proliferation and its underlying mechanism. YC-1 at a range of concentrations (5-50 microM) inhibited DNA synthesis and decreased cell number in cultured HUVEC in a dose- and time-dependent manner. YC-1 was not cytotoxic at these concentrations. [3H]thymidine incorporation and flow cytometry analyses revealed that YC-1 treatment decreased DNA synthesis and arrested the cells at the G0/G1 phase of the cell cycle. Western blot analysis demonstrated that YC-1 (5-50 microM) increased the levels of cyclin-dependent kinase (CDK)-inhibitory proteins (CKIs), p21 and p27, but did not induce any significant changes of cyclins and CDKs. In the YC-1-treated HUVEC, the formation of CDK2-p21 complex, but not CDK2-p27 complex, was increased and the assayable CDK2 kinase activity was decreased. These changes were in a dose-dependent manner. In contrast, the formations of CDK4-p21 and CDK4-p27 complex were slightly increased and the assayable CDK4 kinase activity was slightly decreased (if there were any changes). Pretreatment with guanylyl cyclase inhibitors, 1H-(1,2,4)oxadiazolo[4,3-a]quinozalin-1-one (ODQ) and methylene blue, inhibited the YC-1-induced increase of cyclic GMP level, but did not change significantly the magnitude of the YC-1-induced inhibition of thymidine incorporation and cell number in HUVEC. These results indicate that YC-1-induced cell cycle arrest in HUVEC occurred when the cyclin-CDK system was inhibited just as p21 and p27 protein levels were augmented. This YC-1-induced antiproliferation effect in HUVEC is via a cyclic GMP-independent pathway.
------>tmu_sno=None
------>sno=7169
------>authors2=
------>authors3=
------>authors4=
------>authors5=
------>authors6=
------>authors6_c=None
------>authors=Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM and Lee WS
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway.
------>language=2
------>check_flag=
------>submit_date=
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=
------>publish_year=2003
------>submit_flag=
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z